Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2024

Open Access 01-12-2024 | Blinatumomab | Correspondence

Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting

Authors: Ting Shi, Hong-Hu Zhu

Published in: Journal of Hematology & Oncology | Issue 1/2024

Login to get access

Abstract

The chemo-free concept represents a new direction for managing adult patients with Ph-positive acute lymphoblastic leukemia (Ph + ALL). The tyrosine kinase inhibitors (TKIs), blinatumomab and venetoclax serve as the backbone of chemo-free regimens; several prospective studies involving these drugs have demonstrated high remission rates and promising, albeit short, survival outcomes. This review summarizes the latest updates on chemo-free regimens in the treatment of adult patients with Ph + ALL, presented at the 2023 ASH annual meeting.
Literature
1.
Foà R, Bassan R, Elia L, et al. Long-term results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-positive ALL. J Clin Oncol. 2024;42(8):881–5.CrossRefPubMed
2.
Geyer MB, John Mascarenhas J, Smith M et al. Chemotherapy-sparing induction followed by consolidation and maintenance with Blinatumomab and concurrent oral tyrosine kinase inhibitor therapy for newly-diagnosed Philadelphia chromosome-positive Acute Lymphoblastic Leukemia: primary endpoint results from the Blissphall Study. Blood (2023) 142 (Supplement 1): 1510.
3.
Schwartz M, McMahon CM, Amaya ML et al. Consolidation with Ponatinib Plus Sequential Blinatumomab and Chemotherapy after Low Intensity Dasatinib-based induction in adults with Philadelphia chromosome-positive Acute Lymphoblastic Leukemia: outcomes from a single Institution. Blood (2023) 142 (Supplement 1): 4247.
4.
Chiaretti S, Leoncin M, Elia L et al. Comparison between Dasatinib-Blinatumomab vs Ponatinib-Blinatumomab Chemo-Free Strategy for newly diagnosed Ph + Acute Lymphoblastic Leukemia patients. Preliminary results of the Gimema ALLL2820 Trial. Blood (2023) 142 (Supplement 1): 4249.
5.
Haddad FG, Jabbour E, Short NJ, et al. Chemotherapy-free combination of Blinatumomab and Ponatinib in adults with newly diagnosed Philadelphia chromosome-positive Acute Lymphoblastic Leukemia: updates from a phase II trial. Blood. 2023;142(Supplement 1):2827.
6.
Zhang T, Zhu KB, Cai ZH et al. Frontline Combination of 3 Rd Generation TKI Olverembatinib and Blinatumomab for Ph+/Ph-like ALL patients. Blood (2023) 142 (Supplement 1): 1504.
7.
Gong XY, Fang QY, Gu RX et al. Olverembatinib Combined with Venetoclax and Reduced-Intensity Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study. Blood (2023) 142 (Supplement 1): 827.
8.
Xu GX, Lou YJ, Wang HF et al. Combination of Olverembatinib and VP Regimen as First-Line therapy for adult patients with Philadelphia chromosome-positive Acute Lymphoblastic Leukemia. Blood (2023) 142 (Supplement 1): 4205.
9.
Zhang MM, Hu YX, Wei GQ et al. Dasatinib and CAR-T cell therapy for newly diagnosed Ph-Positive Acute lymphoblastic leukemia in adults. Blood (2023) 142 (Supplement 1): 891.
Metadata
Title
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting
Authors
Ting Shi
Hong-Hu Zhu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2024
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-024-01539-4

Other articles of this Issue 1/2024

Journal of Hematology & Oncology 1/2024 Go to the issue

Review

Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions

Review

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives

Correspondence

Generation of sarconoids from angiosarcoma patients as a systematic-based rational approach to treatment

Review

Vaccines: a promising therapy for myelodysplastic syndrome

Correspondence

Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry

Research

Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits